Miniatura

Fitxers

HondaK.pdf (311.76 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-04-15

Llicència de publicació

cc by (c) Honda, Kazufumi et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/171578

CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/ijc.31900

Resum

Recently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer. Our study provides a first prospective evaluation of an ApoA2 isoform ("ApoA2-ATQ/AT"), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an early detection biomarker for pancreatic cancer. We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma samples collected up to 60 months prior to diagnosis. The detection discrimination statistics were calculated for risk scores by strata of lag-time. For CA19-9, in univariate marker analyses, C-statistics to distinguish future pancreatic cancer patients from cancer-free individuals were 0.80 for plasma taken <= 6 months before diagnosis, and 0.71 for >6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and 0.65, respectively. Joint models based on ApoA2-ATQ/AT plus CA19-9 significantly improved discrimination within >6-18 months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and <= 18 months (C = 0.75 vs. 0.74, p = 0.022). At 98% specificity, and for lag times of <= 6, >6-18 or <= 18 months, sensitivities were 57%, 36% and 43% for CA19-9 combined with ApoA2-ATQ/AT, respectively, vs. 50%, 29% and 36% for CA19-9 alone. Compared to CA19-9 alone, the combination of CA19-9 and ApoA2-ATQ/AT may improve detection of pancreatic cancer up to 18 months prior to diagnosis under usual care, and may provide a useful first measure for pancreatic cancer detection prior to imaging.

Matèries

Càncer de pàncrees, Lipoproteïnes

Matèries (anglès)

Pancreas cancer, Lipoproteins

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

HONDA, Kazufumi, KATZKE, Verena, HUSING, Anika, OKAYA, Shinobu, SHOJI, Hirokazu, ONIDANI, Kaoru, OLSEN, Anja, TJØNNELAND, Anne, OVERVAD, Kim, WEIDERPASS, Elisabete, VINEIS, Paolo, MULLER, David c., TSILIDIS, Kostas, PALLI, Domenico, PALA, Valeria, TUMINO, Rosario, NACCARATI, Alessio, PANICO, Salvatore, ALEKSANDROVA, Krasimira, BOEING, Heiner, BUENO DE MESQUITA, H. bas, PEETERS, Petra h. m., TRICHOPOULOU, Antonia, LAGIOU, Pagona, KHAW, Kay tee, WAREHAM, Nick, TRAVIS, Ruth c., MERINO, Susana, DUELL, Eric j., RODRÍGUEZ BARRANCO, Miguel, CHIRLAQUE, María dolores, BARRICARTE, Aurelio, REBOURS, Vinciane, BOUTRON-RUAULT, Marie-christine, MANCINI, Francesca romana, BRENNAN, Paul, SCELO, Ghislaine, MANJER, Jonas, SUND, Malin, OHLUND, Daniel, CANZIAN, Federico, KAAKS, Rudolf. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation. _International Journal Of Cancer_. 2019-04-15. Vol. 144, núm. Issue 8, pàgs. 1877-1887. [consulta: 23 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/171578]

Exportar metadades

JSON - METS

Compartir registre